<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Projects on Mycobacterial Infection Research Unit</title>
    <link>https://miru-ffm.org/project/</link>
    <description>Recent content in Projects on Mycobacterial Infection Research Unit</description>
    <generator>Source Themes academia (https://sourcethemes.com/academic/)</generator>
    <language>en-us</language>
    <copyright>Copyright &amp;copy; {year}</copyright>
    
	    <atom:link href="https://miru-ffm.org/project/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>ECMO-TB</title>
      <link>https://miru-ffm.org/project/ecmo_tb/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      
      <guid>https://miru-ffm.org/project/ecmo_tb/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Introduction&lt;/strong&gt;: Tuberculosis can cause extensive lung damage leading to respiratory insufficiency. However, data on treatment outcome and clinical course of ECMO therapy in patients with tuberculosis is scarce due to low case numbers.
&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Objectives&lt;/strong&gt;: Investigation of clinical data regarding clinical course and outcome of patients with ECMO therapy and tuberculosis.
&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Methods&lt;/strong&gt;: Literature review, (individual patient data) meta analysis.
&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Status&lt;/strong&gt;: &lt;em&gt;Published&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;&lt;br&gt;
&lt;a href=&#34;https://miru-ffm.org/contact/&#34;&gt;More information&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>FFMTBSEQ</title>
      <link>https://miru-ffm.org/project/ffmtbseq/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      
      <guid>https://miru-ffm.org/project/ffmtbseq/</guid>
      <description>&lt;p&gt;In close collaboration with the muncipial health authorities, the Institute of Medical Microbiology and Infection Control at University Hospital Frankfurt, and the Research Center Borstel, our study group analyses epidemiological and sequencing data that has been generated as part of the PHIMS-TB study under the realms of the RKI.
&lt;br&gt;
&lt;br&gt;
Predictive factors for clinical phenotype, as well as transmission clustering are investigated. This includes the mycobacterial lineage, but also host-determined factors, such as geographpical origin.
&lt;br&gt;
&lt;br&gt;
&lt;a href=&#34;https://miru-ffm.org/contact/&#34;&gt;More information&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>LEVEL-UP-TB</title>
      <link>https://miru-ffm.org/project/leveluptb/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      
      <guid>https://miru-ffm.org/project/leveluptb/</guid>
      <description>&lt;p&gt;Tuberculosis therapy is usuallay administered in weight adapted doses. However, factors like fast-metabolizing enzymes, malabsorption, and drug interactions can influence their serum drug levels. This is not yet taken into account as part of the clinical routine or therapeutic guidelines.&lt;br&gt;
&lt;br&gt;
&lt;br&gt;
The LEVEL-UP-TB project evaluates different factors predicting serum drug levels of antimycobacterial therapy as well as their influence on therapeutic outcome.
&lt;br&gt;
&lt;br&gt;
&lt;a href=&#34;https://miru-ffm.org/#contact&#34;&gt;Contact PI&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>NTM-registry</title>
      <link>https://miru-ffm.org/project/registry/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      
      <guid>https://miru-ffm.org/project/registry/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Introduction&lt;/strong&gt;: In contrast to tuberculosis, infections due to non-tuberculous mycobacteria (NTM) are not notifiable. However, there is accumulating evidence that their incidence is increasing in countries with low endemicity of tuberculosis. In addition, the pathogenicity of different NTM varies widely.
&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Objectives&lt;/strong&gt;: Investigation of the epidemiological and clinical features of patients infected or colonised with non-tuberculous mycobacteria (NTM).
&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Methods&lt;/strong&gt;: The ntmscope_registry will establish needed data collecting tools in a monocentric approach, after an initial test phase the registry will become available to additional centers with the aim of becoming the first NTM-registry in Germany. This is to be achieved with the Institute for Medical Informatics (IMI) of the Goethe University Frankfurt.
&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Status&lt;/strong&gt;: &lt;em&gt;Registry currently being constructed&lt;/em&gt;&lt;br&gt;
&lt;br&gt;
&lt;br&gt;
&lt;a href=&#34;https://www.osse-register.de/&#34;&gt;www.osse-register.de&lt;/a&gt;
&lt;br&gt;
&lt;br&gt;
&lt;a href=&#34;https://miru-ffm.org/contact/&#34;&gt;More information&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>NTMscope-Eco</title>
      <link>https://miru-ffm.org/project/eco/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      
      <guid>https://miru-ffm.org/project/eco/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Introduction&lt;/strong&gt;: Non-tuberculous mycobacteria (NTM) are recovered from a variety of environmental samples. In other countries, potable water, for example from shower heads, has been a frequent source. Patients with NTM-pulmonary disease have been shown to acquire their bacterial isolates from their household water samples in some cases. However, in Germany, NTM have not been isolated from water samples until now and only been found in soil, dust, and others.&lt;/p&gt;
&lt;p&gt;&lt;br&gt;
&lt;strong&gt;Objectives&lt;/strong&gt;: Isolation of NTM from water samples.
&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Methods&lt;/strong&gt;: Environmental sampling, culture, molecular identification techniques.&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Status&lt;/strong&gt;: &lt;em&gt;Published&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;&lt;br&gt;
&lt;a href=&#34;https://miru-ffm.org/contact/&#34;&gt;More information&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>NTMscope-MAC</title>
      <link>https://miru-ffm.org/project/ntmscope-mac/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      
      <guid>https://miru-ffm.org/project/ntmscope-mac/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Introduction&lt;/strong&gt;: &lt;em&gt;M. avium&lt;/em&gt; complex is the predominant slow-growing mycobacterium in Europe and North America and consists – among others – of the species &lt;em&gt;M. avium, M. intracellulare&lt;/em&gt; and &lt;em&gt;M. chimaera&lt;/em&gt;. The latter has been involved in a global outbreak of infections in patients that underwent cardiosurgical interventions. Here, contaminated heater-cooler machines could be identified as point infection source. All three species are present in the environment and have been isolated from water sources in patient homes. However, human-to-human transmission has not been established so far. In CF-patients, &lt;em&gt;M. avium&lt;/em&gt; complex is the NTM second most frequently isolated in Europe. If there are dominant circulating clones, as has been described in &lt;em&gt;M. abscessus&lt;/em&gt;, remains unclear until now.&lt;/p&gt;
&lt;p&gt;&lt;br&gt;
&lt;strong&gt;Objectives&lt;/strong&gt;: Investigation of the genomic epidemiology of &lt;em&gt;M. avium&lt;/em&gt; complex in multiple centers in Europe.
&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Methods&lt;/strong&gt;: Clinical and epidemiological data-analysis, whole genome sequencing, genotypic drug susceptibility testing.&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Status&lt;/strong&gt;: &lt;em&gt;Published&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;&lt;br&gt;
&lt;a href=&#34;https://www.ebi.ac.uk/ena/browser/view/PRJEB70863&#34;&gt;European Nucleotide Archive&lt;/a&gt;&lt;br&gt;
&lt;br&gt;
&lt;a href=&#34;https://miru-ffm.org/ntmscope_mac_microreact&#34;&gt;Microreact project&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>NTMscope-Meta</title>
      <link>https://miru-ffm.org/project/meta/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      
      <guid>https://miru-ffm.org/project/meta/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Introduction&lt;/strong&gt;: Treatment and management of rare NTM remains a considerable challenge as randomized controlled trials or systematic studies are scarce. Most therapeutic recommendations are based on &lt;em&gt;in vitro&lt;/em&gt; data or clinical experience with more frequent NTM. The optimal therapy for most infections remains unclear.
&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Objectives&lt;/strong&gt;: Investigation of clinical data regarding the clinical manifestations and therapeutic outcomes of rare NTM.
&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Methods&lt;/strong&gt;: Literature review, (individual patient data) meta analysis.
&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Status&lt;/strong&gt;: &lt;em&gt;Ongoing&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;&lt;br&gt;
&lt;a href=&#34;https://miru-ffm.org/contact/&#34;&gt;More information&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>NTMscope-REPLAGE</title>
      <link>https://miru-ffm.org/project/ntmscope-replage/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      
      <guid>https://miru-ffm.org/project/ntmscope-replage/</guid>
      <description>&lt;p&gt;The group of non-tuberculous mycobacteria (NTM) comprises all mycobacteria except &lt;em&gt;M. tuberculosis&lt;/em&gt; and &lt;em&gt;M. leprae&lt;/em&gt;. The incidence of NTM-infections is rising globally. Due to intrinsic antibiotic resistances, they are extremely difficult to treat and associated with severe consequences for individual patients. NTMscope-REPLAGE will use an unique European dataset to characterize resistance determinants, the plasmidome and possible phage therapies in different NTM species. Through the correlation of genotypic and phenotypic susceptibility testing, further resistance genes will be identified and allow a prediction of phenotypic susceptibility based on genomic data. A comprehensive characterization of the plasmidome of NTM will identify plasmids as possible carriers of resistance and virulence genes. Finally, the general susceptibility of different NTM-species to lytic mycobacteriophages will be determined. By combining these different methodological approaches, NTMscope-REPLAGE will facilitate individualized therapies, allow stratified risk assessment by improved diagnostics and therefore contribute significantly to the better management of difficult to treat NTM-infections.&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Funding&lt;/strong&gt;: BMBF
&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Status&lt;/strong&gt;: &lt;em&gt;Project ongoing&lt;/em&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>STRIDE-TB</title>
      <link>https://miru-ffm.org/project/stride_tb/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      
      <guid>https://miru-ffm.org/project/stride_tb/</guid>
      <description>&lt;p&gt;This project aims to explore sex and gender differences in tuberculosis by systematically evaluating and summarizing the available evidence. It will focus on key aspects such as tuberculosis epidemiology, manifestation, covering both extrapulmonary and pulmonary tuberculosis, and treatment factors such as monitoring, duration, and outcomes like mortality and TB sequelae. The goal is to understand whether and how tuberculosis progresses differently between men and women, how treatment responses vary, and what the health consequences are.&lt;br&gt;
&lt;br&gt;
&lt;br&gt;
&lt;br&gt;
&lt;a href=&#34;https://miru-ffm.org/contact/&#34;&gt;More information&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>SURVERY-TB</title>
      <link>https://miru-ffm.org/project/survery_tb/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      
      <guid>https://miru-ffm.org/project/survery_tb/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Introduction&lt;/strong&gt;: Tuberculosis can cause extensive lung damage. This might contribute to prolonged therapies and adverse outcomes. In some patients, adjunctive therapy might be useful. However, there are no large studies and the landscape of existing experience regarding surgery in patients with pulmonary tuberculosis is limited.
&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Objectives&lt;/strong&gt;: To draw a detailed picture on existing experience of the usage of adjunctive surgery in patients with pulmonary tuberculosis.
&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Methods&lt;/strong&gt;: Survey of health professionals.
&lt;br&gt;
&lt;br&gt;
&lt;strong&gt;Status&lt;/strong&gt;: &lt;em&gt;Survey ongoing&lt;/em&gt;
&lt;br&gt;
&lt;br&gt;
&lt;a href=&#34;https://docs.google.com/forms/d/e/1FAIpQLScuRXMYVdY122eXSkMqKjSIj8r3pgfXvcY-dkK0-XOunE-WaQ/viewform&#34;&gt;Participate&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;&lt;br&gt;
&lt;a href=&#34;https://miru-ffm.org/contact/&#34;&gt;More information&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>TRACE-TB</title>
      <link>https://miru-ffm.org/project/trace_tb/</link>
      <pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate>
      
      <guid>https://miru-ffm.org/project/trace_tb/</guid>
      <description>&lt;p&gt;The aim of this project is to evaluate biomarkers for the diagnosis of mycobacterial diseases. Existing diagnostic methods are often too slow, inaccurate or carry the risk of spreading infection, which makes early and specific treatment difficult. The TRACE-TB project therefore aims to validate promising biomarker candidates in different clinical cohorts. In addition, new markers are to be investigated using a proteomics approach.
&lt;br&gt;
&lt;br&gt;
&lt;a href=&#34;https://miru-ffm.org/contact/&#34;&gt;More information&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
